Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith M G van Esch

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|November 2, 2022
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesionsZiena Abdulrahman, Natasja Hendriks, Arnold J Kruse, et al.
Journal of Translational Medicine|April 6, 2013
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trialMariette I E van Poelgeest, Marij J P Welters, Edith M G van Esch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2016
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell ResponseMariëtte I E van Poelgeest, Marij J P Welters, Renee Vermeij, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|November 2, 2022
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesionsZiena Abdulrahman, Natasja Hendriks, Arnold J Kruse, et al.
Journal of Translational Medicine|April 6, 2013
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trialMariette I E van Poelgeest, Marij J P Welters, Edith M G van Esch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2016
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell ResponseMariëtte I E van Poelgeest, Marij J P Welters, Renee Vermeij, et al.
Pageof 3